According to the study’s abstract, the Atenolol study of 1996 demonstrated that perioperative beta-blockade reduced post-surgical mortality. The current study tests whether a difference exists in mortality rates between patients receiving perioperative atenolol and metoprolol.
The study divided high-risk inpatients at San Francisco Veterans Affairs Medical Center since 1996 into two groups: patients who received perioperative atenolol only and patients who received metoprolol only. Propensity matching analysis was used to correct for differences in population risk factors.
The analysis showed that thirty-year mortality and one-year mortality was less likely for patients receiving atenolol than those receiving metoprolol.
Read the abstract on the study in Anesthesiology.
Read more on anesthesia:
–Anesthesiologist on the Move: Dr. Michael Semenovski Joins BAETA as CMO
–Mass General Anesthesiologists to Provide Coverage at Martha’s Vineyard Hospital
–Botox-A Provides Only Limited Pain Relief for Cervical Myofascial Pain Syndrome
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.